Stryker (SYK)
NYSE: SYK · Medical Devices · Portage, MI
Our rating: Positive
Positive reaffirmed at $306.81, moderate conviction, November 2, 2026.
Breaks if: The Positive call is wrong if reported revenue growth falls below 7% for two consecutive quarters within the next four reported periods — roughly halving the current pace — or if trailing twelve-month free cash flow drops below $3.5 billion, signaling that the cash-conversion quality we are relying on is narrowing. Either condition would undercut the growth premium embedded in a 36.5x P/E. The call would step toward Conviction if net margin demonstrates a clear trend toward 15% across two straight quarters while top-line growth holds above 9%.
Key figures
| Market value | $118.0B |
|---|---|
| Revenue, last 12 months | $26.3B |
| Net income, last 12 months | $3.6B |
| Free cash flow, last 12 months | $4.6B |
| Price to earnings | 32.6× |
| Free cash flow yield | 3.9% |
| Dividend yield | 1.1% |
| Operating margin | 20.7% |
| Return on equity | 16.0% |
| Beta to the S&P 500 | 0.54 |
| Volatility, annualized | 26.2% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $6.5B | 7.6% | $1.96 | $1.2B |
| June 30, 2026 | $6.6B | 9.4% | $3.30 | $1.1B |
| March 31, 2026 | $6.0B | 2.6% | $1.93 | $415M |
| December 31, 2025 | $7.2B | 11.4% | $2.20 | $1.9B |
| September 30, 2025 | $6.1B | 10.2% | $2.22 | $1.4B |
| June 30, 2025 | $6.0B | 11.1% | $2.29 | $928M |
| March 31, 2025 | $5.9B | 11.9% | $1.69 | $127M |
| December 31, 2024 | $6.4B | 10.7% | $1.41 | $1.7B |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $7.73B: Claude 62%, Gemini 45%, Mistral 62%
- Diluted earnings per share are at least $2.20: Claude 55%, Gemini 62%, Mistral 54%
- Free cash flow for the quarter is at least $1.88B: Claude 52%, Gemini 58%, Mistral 48%
22 ledger entries and 42 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.